A Randomized, Double-blind, Phase 2, Placebo Controlled Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The Topic Trial)
Latest Information Update: 23 Dec 2023
Price :
$35 *
At a glance
- Drugs Ivacaftor (Primary)
- Indications Chronic bronchitis; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Acronyms The Topic Trial
- 29 Mar 2023 Status changed from recruiting to completed.
- 24 Mar 2022 Planned End Date changed from 1 Apr 2022 to 1 Mar 2023.
- 24 Mar 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Mar 2023.